You just read:

Agenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda®, Merck & Co., Inc.) with Prophage™ (Agenus Inc.) autologous vaccine

News provided by

Agenus Inc.

17 Jan, 2017, 09:00 ET